The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1376
October 31, 2011
View Complete Issue         Table of Contents 2019 
A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)
October 31, 2011 (Issue: 1376)
The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)
Article code: 1376a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.